Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Target Recruit Count
- 43
- Registration Number
- NCT06492629
- Locations
- 🇨🇳
Department of Medical Oncology, Beijing, Beijing, China
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06457503
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT06441344
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
- Conditions
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 478
- Registration Number
- NCT06437977
Toripalimab for High-risk Locally Advanced Cervical Cancer
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 130
- Registration Number
- NCT06416696
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT06389006
- Locations
- 🇨🇳
Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06389526
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 74
- Registration Number
- NCT06387628
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 32
- Registration Number
- NCT06371274
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P.R. China, China
Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06362317
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.